Advertisement
Advertisement
PRTA
Prothena Corporation plc Ordinary Shares
9.51
USDSponsored
+0.20
+2.11%
Mar 26, 15:59 UTC -4
Closed
After-Market
9.52
+0.01
+0.15%
PRTA Earnings Reports
Positive Surprise Ratio
PRTA beat 19 of 40 last estimates.
48%
Next Report
Date of Next Report
May 06, 2026
Estimate for Q1 26 (Revenue/ EPS)
$824.16K
/-$0.35
Implied change from Q4 25 (Revenue/ EPS)
+3824.57%
/-12.50%
Implied change from Q1 25 (Revenue/ EPS)
-70.86%
/-68.75%
Prothena Corporation plc Ordinary Shares earnings per share and revenue
On Feb 19, 2026, PRTA reported earnings of -0.40 USD per share (EPS) for Q4 25, beating the estimate of -0.56 USD, resulting in a 29.82% surprise. Revenue reached 21.00 thousand, compared to an expected 1.42 million, with a -98.52% difference. The market reacted with a +1.24% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 4 analysts forecast an EPS of -0.35 USD, with revenue projected to reach 824.16 thousand USD, implying an decrease of -12.50% EPS, and increase of 3824.57% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Precigen, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.24%
Absci Corporation Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.04%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
LENZ Therapeutics, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.99
Actual
-$1.15
Surprise
-17.10%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.03
Actual
-$0.11
Surprise
-408.12%
Equillium, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+35.28%
MaxCyte, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.06
Surprise
+26.47%
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
TELA Bio, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.12%
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
FAQ
What were Prothena Corporation plc Ordinary Shares's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Prothena Corporation plc Ordinary Shares reported EPS of -$0.40, beating estimates by 29.82%, and revenue of $21.00K, -98.52% below expectations.
How did the market react to Prothena Corporation plc Ordinary Shares's Q4 2025 earnings?
The stock price moved up 1.24%, changed from $8.85 before the earnings release to $8.96 the day after.
When is Prothena Corporation plc Ordinary Shares expected to report next?
The next earning report is scheduled for May 06, 2026.
What are the forecasts for Prothena Corporation plc Ordinary Shares's next earnings report?
Based on 4
analysts, Prothena Corporation plc Ordinary Shares is expected to report EPS of -$0.35 and revenue of $824.16K for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement